WuXi XDC Cayman Inc., a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that it has been named the winner of "Best CDMO" at the 2026 World ADC Awards for the fourth consecutive year, along with the winner of "Best CRO" for the second consecutive year. WuXi XDC was the only CRDMO to claim both honors for two consecutive years in this year's awards. These awards not only recognize the Company's excellence in end-to-end, one-stop CRDMO services and innovative R&D capabilities, but also affirm its global leadership in the bioconjugate industry.
As one of the most influential annual awards in the global ADC sector, the World ADC Awards honor companies, teams and innovations that have made outstanding contributions to the field. This year's World ADC Conference brought together global experts, scholars, and industry leaders to focus on the full lifecycle progress of ADCs and XDCs, from R&D stage to commercialization, as well as the latest breakthroughs in bioconjugates.
Dr. Jimmy Li, CEO of WuXi XDC, stated, "We are proud to have been named the winner of 'Best CDMO' for the fourth consecutive year and 'Best CRO' for the second consecutive year. We are also more aware than ever of the weight of this trust and thank our global clients and partners for their continued support. As the demand for bioconjugates becomes increasingly diverse, WuXi XDC will continue to be grounded in technological innovation, supported by global collaboration and high-quality delivery, and empower our clients to advance bioconjugates to clinical and commercial stages faster and more reliably, creating greater value for the industry and patients."